US 11,788,143 B2
Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
Yonghong Li, Palo Alto, CA (US); Steven Schrodi, Madison, WI (US); Ann Begovich, El Cerrito, CA (US); and Monica Chang, Oakland, CA (US)
Assigned to Celera Corporation, San Juan Capistrano, CA (US)
Filed by CELERA CORPORATION, San Juan Capistrano, CA (US)
Filed on Feb. 17, 2021, as Appl. No. 17/177,433.
Application 17/177,433 is a division of application No. 16/149,492, filed on Oct. 2, 2018, granted, now 10,954,565.
Application 13/080,458 is a division of application No. 12/325,832, filed on Dec. 1, 2008, granted, now 7,947,451, issued on May 24, 2011.
Application 16/149,492 is a continuation of application No. 14/963,923, filed on Dec. 9, 2015, granted, now 10,131,949.
Application 14/963,923 is a continuation of application No. 13/657,215, filed on Oct. 22, 2012, abandoned.
Application 13/657,215 is a continuation of application No. 13/080,458, filed on Apr. 5, 2011, abandoned.
Claims priority of provisional application 61/005,018, filed on Nov. 30, 2007.
Prior Publication US 2021/0317530 A1, Oct. 14, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12P 19/34 (2006.01); C12Q 1/6883 (2018.01); G01N 33/68 (2006.01)
CPC C12Q 1/6883 (2013.01) [G01N 33/6881 (2013.01); G01N 33/6893 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/136 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/172 (2013.01); G01N 2500/04 (2013.01); G01N 2800/065 (2013.01); G01N 2800/205 (2013.01); G01N 2800/50 (2013.01)] 15 Claims
 
1. A method for reducing the risk of psoriasis in a human, the method comprising:
a) testing nucleic acid from said human for a polymorphism in gene IL13 as represented by position 101 of SEQ ID NO:22 or its complement by contacting said nucleic acid with an oligonucleotide that specifically hybridizes to C at said position 101 of SEQ ID NO:22 or G at said complement;
b) detecting said C or said G;
c) identifying said human as having an increased risk for psoriasis due to the presence of said C or said G; and
d) administering a therapeutic agent suitable for prevention or treatment of psoriasis to said human.